Overview
Epia Neuro develops neural technologies to restore function for people with neurological conditions. Its lead platform uses a minimally invasive cranial implant with a wireless read/write brain–computer interface and AI software to translate neural intent into actions, fusing brain signals with external sensors to drive assistive devices like a grip-assist glove. The implant sits in the skull in under an hour, is wirelessly rechargeable, and modular to allow future upgrades without additional surgery. The goal is to restore daily independence for stroke survivors and expand to cognitive decline and other neurological disorders, targeting a multi‑billion-dollar market.
Work here?Claim your company
Simplify's take
What believers are saying
- Epia Neuro launched April 2, 2026, and ranked #4 on LinkedIn's 2026 startups.
- The company reported 45 employees in April 2026 and 11 open roles by November 2026.
- June 2026 funding included venture and pharmaceutical capital, supporting clinical execution this year.
What critics are saying
- First-in-human demos at Lenox Hill in 2026 remain unproven, with no human outcomes.
- February 2027 FDA submission is aggressive; any safety issue stalls stroke and cognitive programs.
- Neuralink and Merge Labs dwarf Epia Neuro; one failed trial could kill reimbursement and adoption.
What makes Epia Neuro unique
- Skull-mounted, non-penetrating implant targets stroke recovery and lifelong assistive use.
- Epia Neuro pairs neural intent decoding with a replaceable grip-assist glove.
- Michel Maharbiz brings iota Biosciences experience; Gil Mandelbaum built the platform in stealth.
Help us improve and share your feedback! Did you find this helpful?